Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 113Lymphoma, Mantle-Cell 65Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Lymphoma, B-Cell 22Recurrence 21Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × ibrutinib × Clear all
NCT03525925 2024-03-18

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡